VERU INC. - COMMON STOCK

Veru Reports Fiscal 2023 First Quarter Financial Results

09 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

26 1 2023 08:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

10 1 2023 08:30:00 提供 Nasdaq GlobeNewswire

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

05 12 2022 06:30:00 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

28 11 2022 08:30:00 提供 Nasdaq GlobeNewswire

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

09 11 2022 20:55:21 提供 Nasdaq GlobeNewswire

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

24 10 2022 08:30:00 提供 Nasdaq GlobeNewswire

Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

13 10 2022 08:30:00 提供 Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04 10 2022 16:30:00 提供 Nasdaq GlobeNewswire

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

21 9 2022 08:30:00 提供 Nasdaq GlobeNewswire

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

19 9 2022 12:15:00 提供 Nasdaq GlobeNewswire

Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

07 9 2022 13:45:00 提供 Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022

06 9 2022 08:30:01 提供 Nasdaq GlobeNewswire

Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

22 8 2022 08:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

19 8 2022 08:30:00 提供 Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 8 2022 16:30:00 提供 Nasdaq GlobeNewswire

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

11 8 2022 06:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022

09 8 2022 08:30:01 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th

28 7 2022 08:30:01 提供 Nasdaq GlobeNewswire

European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries

27 7 2022 11:00:00 提供 Nasdaq GlobeNewswire